RICHARD A CARTER
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology CONYERS, GA NPI 1083660104
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology GA PFIZER INC. All categories
General Payments — all program years on this page
$7,330.64
- Category: General Payments
- Program years: PY2018–2024
- Record count: 296
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,780.95 across 82 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,780.95 | 82 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $289.12 | 17 |
| BeiGene USA, Inc. | $179.96 | 4 |
| Acerta Pharma LLC | $122.36 | 6 |
| Janssen Biotech, Inc. | $114.87 | 6 |
| Daiichi Sankyo Inc. | $112.08 | 4 |
| ABBVIE INC. | $89.37 | 5 |
| Alexion Pharmaceuticals, Inc. | $85.30 | 4 |
| Merck Sharp & Dohme Corporation | $62.60 | 3 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $58.62 | 3 |
| Celgene Corporation | $49.97 | 2 |
| Stemline Therapeutics Inc. | $49.11 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $46.21 | 2 |
| Lilly USA, LLC | $43.92 | 2 |
| ARRAY BIOPHARMA INC | $43.41 | 4 |
| EISAI INC. | $42.40 | 2 |
| JAZZ PHARMACEUTICALS INC. | $38.98 | 1 |
| PharmaEssentia USA Corporation | $37.24 | 2 |
| Genentech USA, Inc. | $34.33 | 2 |
| Ipsen Biopharmaceuticals, Inc | $33.20 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $30.35 | 1 |
| Karyopharm Therapeutics Inc. | $30.28 | 1 |
| Pharmacosmos Therapeutics Inc. | $27.38 | 1 |
| Astellas Pharma US Inc | $26.46 | 1 |
| GENZYME CORPORATION | $25.50 | 1 |
| PUMA BIOTECHNOLOGY, INC. | $25.21 | 1 |
| Sirtex Medical Inc | $23.75 | 1 |
| GlaxoSmithKline, LLC. | $21.92 | 1 |
| SOBI, INC | $19.22 | 1 |
| Agios Pharmaceuticals, Inc. | $17.83 | 1 |
By program year
Records — PY2024 (82)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.